Twitter | Pretraživanje | |
steve usdin
Washington Editor, BioCentury. Author: Bureau of Spies & Engineering Communism.
2.607
Tweetovi
261
Pratim
1.817
Osobe koje vas prate
Tweetovi
steve usdin 12 h
Today: WHO says Gilead’s remdesivir most promising drug for #2019-nCoV. WHO plans master protocol to test multiple therapies. FDA authorizes emergency use Dx. HHS funds Regeneron coronavirus antibody. And more at . No paywall.
Reply Retweet Označi sa "sviđa mi se"
steve usdin proslijedio/la je tweet
Jeffrey Cranmer 15 h
. draft report: 's remdesivir most "promising" candidate to treat , planning for trial under way. says its “investing pretty heavily” in manufacturing of the therapy “to make sure we’re prepared as best as we can” via
Reply Retweet Označi sa "sviđa mi se"
steve usdin 15 h
WHO expert group says Gilead's remdesivir most promising to treat #2019-nCoV, then protease inhibitors. MERS antibodies not likely to work.
Reply Retweet Označi sa "sviđa mi se"
steve usdin 15 h
WHO prioritizing Gilead's remdesivir, designing master protocol to test multiple drug for 2019-nCoV outbreak
Reply Retweet Označi sa "sviđa mi se"
steve usdin proslijedio/la je tweet
Derek Lowe 4. velj
(1/2) I wanted to highlight two sources of coronavirus news which some respected biopharma news sources have placed in front of their usual paywalls. Here's Biocentury's coverage:
Reply Retweet Označi sa "sviđa mi se"
steve usdin proslijedio/la je tweet
Josh Berlin 4. velj
We have created a free webpage that collects analysis of the outbreak. Please bookmark this page. It will be updated frequently. The most recent story tracks clinical trials.
Reply Retweet Označi sa "sviđa mi se"
steve usdin 4. velj
Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: . At least 9 trials of #2019-nCoV therapies are underway. All BioCentury coverage of the outbreak is in front of the paywall at .
Reply Retweet Označi sa "sviđa mi se"
steve usdin 4. velj
Data will be critical to curtailing the #2019-nCoV outbreak. It looks like China is starting trials to gather data about treatments: . List of 9 trials below. Also Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: .
Reply Retweet Označi sa "sviđa mi se"
steve usdin 4. velj
Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: . Meanwhile, at least 9 trials of #2019-nCoV therapies are underway. All BioCentury coverage of the outbreak is in front of the paywall at .
Reply Retweet Označi sa "sviđa mi se"
steve usdin 3. velj
FDA, FTC vow to crack down on advertising and commercial practices that impede biosimilar uptake
Reply Retweet Označi sa "sviđa mi se"
steve usdin 3. velj
This will stretch supplies of vaccines, which could be important in a pandemic. Also could make vaccines more effective if #2019-nCoV "drifts."
Reply Retweet Označi sa "sviđa mi se"
steve usdin 3. velj
An elegant explanation of an important study by the founder of Immuno-oncology - Steve Rosenberg. He has found a way to make T cell therapies by taking T cells from blood rather than from tumors, which is far less invasive.
Reply Retweet Označi sa "sviđa mi se"
steve usdin 3. velj
GlaxoSmithKline to make its immune-boosting adjuvant technology available to #2019-nCoV vaccine makers. This will dramatically stretch supplies and could make vaccines more effective. The agreement covers 4 groups making vaccines funded by CEPI.
Reply Retweet Označi sa "sviđa mi se"
steve usdin proslijedio/la je tweet
BioCentury 3. velj
GSK to provide adjuvant to boost effectiveness and stretch supplies of vaccines
Reply Retweet Označi sa "sviđa mi se"
steve usdin 1. velj
Another thing to consider re #2019-nCoV: China has become integrated into global drug development. China in general, and Wuhan in particular, are the sites of many drug trials. These aren't likely to priorities in a public health emergency.
Reply Retweet Označi sa "sviđa mi se"
steve usdin proslijedio/la je tweet
Susan Schaeffer 1. velj
I'm excited to join this March 24 workshop on digital health as a new member of 's Forum on Drug Discovery, Development, and Translation. The workshop is open to the public! Details below:
Reply Retweet Označi sa "sviđa mi se"
steve usdin 31. sij
HHS declares #2019-nCoV a public health emergency. Separate declarations will be needed to allow FDA to issue Emergency Use Authorizations (EUAs), e.g., for use of unapproved diagnostics.
Reply Retweet Označi sa "sviđa mi se"
steve usdin 31. sij
Odgovor korisniku/ci @Youcef_Mehellou @GileadSciences
These lists are of programs to develop new vaccines and therapies. I've mentioned Gilead in previous stories about efforts to repurpose existing products.
Reply Retweet Označi sa "sviđa mi se"
steve usdin 31. sij
A dozen #2019-nCoV vaccine development programs have been announced, five efforts to discover and develop therapeutic antibodies.
Reply Retweet Označi sa "sviđa mi se"
steve usdin 31. sij
Biotech boards and C-suites are still overwhelmingly white and male.
Reply Retweet Označi sa "sviđa mi se"